Soluble CD83 ameliorates experimental colitis in mice

Mucosal Immunology

Volumn 7, Issue 4, 2014, Pages 1006-1018

  Eckhardt, J ^a   Kreiser, S ^a   Dobbeler M ^a   Nicolette, C ^b   Debenedette, M A ^b   Tcherepanova, I Y ^b   Ostalecki, C ^a   Pommer, A J ^a   Becker, C ^a   Gunther C ^a   Zinser, E ^a   Mak, T W ^c   Steinkasserer, A ^a   Lechmann, M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Argos Therapeutics Inc   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD83 ANTIGEN; CYCLOOXYGENASE 2; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; DEXTRAN SULFATE; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; COLON; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL COLITIS; GRANULOCYTE; LEUKOCYTE; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS; DISEASE MODEL; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MESENTERY; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; GENE EXPRESSION; IMMUNOGLOBULINS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LEUKOCYTES; LYMPH NODES; MEMBRANE GLYCOPROTEINS; MESENTERY; MICE;

EID: 84902585744     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.119     Document Type: Article

References (45)

1. Garrett,W.S., Gordon, J.I. &Glimcher, L.H. Homeostasis and inflammation in the intestine. Cell 140, 859-870 (2010
2. Strober, W., Fuss, I. & Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Inv 117, 514-521 (2007
3. Laroux, F.S. & Grisham, M.B. Immunological basis of inflammatory bowel disease: Role of microcirculation. Microcirculation 8, 283-301 (2001
4. Sartor, R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577-594 (2008
5. Colombel, J.F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 5, 1383-1395 (2010
6. Prechtel, A.T., Turza, N.M., Theodoridis, A.A. & Steinkasserer, A. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA (siRNA) leads to a diminished T-cell stimulation. J. Immunol 178, 5454-5464 (2007
7. Prazma, C.M., Yazawa, N., Fujimoto, Y., Fujimoto, M. & Tedder, T.F. CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J. Immunol 179, 4550-4562 (2007
8. Hock, B.D., Kato, M., McKenzie, J.L. & Hart, D.N. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int. Immunol 13, 959-967 (2001
9. Hock, B.D., Haring, L.F., Steinkasserer, A., Taylor, K.G., Patton, W.N. & McKenzie, J.L. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk. Res. 28, 237-241 (2004
10. Hock, B.D., Fernyhough, L.J., Gough, S.M., Steinkasserer, A., Cox, A.G. & McKenzie, J.L. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk. Res. 33, 1089-1095 (2009
11. Sé né chal, B., Boruchov, A.M., Reagan, J.L., Hart, N. & Young, J.W. Infection of mature monocyte derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 103, 4207-4215 (2004
12. Lechmann, M. et al. The extracellular domain of CD83 inhibits DCmediated Tcell stimulation and binds to a ligand on Dendritic cells. J. Exp. Med 194, 1813-1821 (2001
13. Scholler, N., Hayden-Ledbetter, M., Dahlin, A., Hellström, I., Hellström, K.E. & Ledbetter, J.A. CD83 regulates the development of cellular immunity. J. Immunol. 168, 2599-2602 (2002
14. Lan, Z. et al. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2, 3-dioxygenase. Transplantation 90, 1286-1293 (2010
15. Zinser, E., Lechmann, M., Golka, A., Lutz, M.B. & Steinkasserer, A. Prevention and treatment of experimental autoimmune encephalomyelitis (EAE) by soluble CD83. J. Exp. Med. 200, 345-351 (2004
16. Xu, J.F. et al. Alimited course of solubleCD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transpl. Int 20, 266-276 (2007
17. Ge, W. et al. Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection. Transplantation 90, 1145-1156 (2010
18. Lechmann, M., Shuman, N.,Wakeham, A. & Mak, T.W. The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo. Proc. Natl. Acad. Sci. USA 105, 11887-11892 (2008
19. Hawkins, J.V. et al. Protease activity in a hapten-induced model of ulcerative colitis. Dig. Dis. Sci 42, 1969-1980 (1997
20. Neurath, M.F., Fuss, I., Kelsall, B.L., Stüber, E. & Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290 (1995
21. Spadoni, I., Iliev, I.D., Rossi, G. & Rescigno, M. Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis. Mucosal Immunol 5, 184-193 (2012
22. Reardon, C. et al. Thymic stromal lymphopoetin-induced expression of the endogenous inhibitory enzyme SLPI mediates recovery from colonic inflammation. Immunity 35, 223-235 (2011
23. Munn, D.H., Shafizadeh, E., Attwood, J.T., Bondarev, I., Pashine, A. & Mellor, A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999
24. Mellor, A.L. & Munn, D.H. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774 (2004
25. Pallotta, M.T. et al. Indoleamin 2,3-dioxygenase is a signaling protein in long-Term tolerance by dendritic cells. Nat. Immunol 12, 870-878 (2011
26. Okamoto, T., Toné, S., Kanouchi, H.,Miyawaki, C., Ono, S. & Minatogawa, Y. Transcriptional regulation of indoleamine 2, 3-dioxygenase (IDO) by tryptophan and its analogue. Cytotech 54, 107-113 (2007
27. Pithadia, A.B. & Jain, S. Treatment of inflammatory bowel disease (IBD). Pharmacol. Reports 63, 629-642 (2011
28. Gonzalez-Rey, E., Chorny, A. & Delgado, M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7, 52-63 (2007
29. Abad, C. et al. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: Homeostatic role of VIP. Inflamm. Bowel. Dis 11, 674-684 (2005
30. Arranz, A., Abad, C., Juarranz, Y., Leceta, J., Martinez, C. & Gomariz, R.P. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 15, 46-53 (2008
31. Chen,W.J. IDO: More than an enzyme. Nat. Immunol. 12, 809-811 (2011
32. Breloer, M. & Fleischer, B. CD83 regulates lymphocyte maturation, activation and homeostasis. Trends Immunol. 29, 186-194 (2008
33. Wirtz, S. & Neurath, M.F. Mouse models of inflammatory bowel disease. Adv. Drug Deliv. Rev. 59, 1073-1083 (2007
34. Massa, F. et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest 113, 1202-1209 (2004
35. Reardon, C.,Wang, A. &McKay, D.M. Transient local depletion of Foxp3+ regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death. J. Immunol 180, 8316-8326 (2008
36. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533 (2003
37. Taylor, M.W. & Feng, G.S. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 5, 2516-2522 (1991
38. Bock, F. et al. Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. J. Immunol. 191, 1965-1975 (2013
39. Gurtner, G.J., Newberry, R.D., Schloemann, S.R., McDonald, K.G. & Stenson, W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125, 1762-1773 (2003
40. Van Der Sluijs, K., Singh, R., Dijkhuis, A., Snoek, M. & Lutter, R. Indoleamine-2,3-dioxygenase activity induces neutrophil apoptosis. Crit. Care 15 (Suppl 1), P208 (2011
41. Hunter,M.M.,Wang, A., Hirota, C.L. &McKay, D.M. Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically-induced colitis. J. Immunol 174, 7368-7375 (2005
42. Xu, Y. et al. Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein. Protein Expr. Purif 65, 92-99 (2009
43. Becker, C., Fantini, M.C. & Neurath, M.F. High resolution colonoscopy in live mice. Nat. Prot 1, 2900-2904 (2006
44. Schubert, W. et al. Analyzing proteome topology and function by automated multi-dimensional fluorescence microscopy. Nat. Biotechnol 24, 1270-1278 (2006
45. Eckhardt, J., Ostalecki, C., Kuczera, K., Schuler, G., Pommer, A.J. & Lechmann,M.Murinewhole-organimmune cell populations revealed bymultiepitope-ligand cartography. J. Histochem. Cytochem. 61, 125-133 (2013.